News
-
CTN+ to lead Canada’s HIV and STBBI clinical trial infrastructure with $25 million investment from CIHR
On July 12th, 2024, the Canadian Institutes for Health Research (CIHR) announced a $25 million investment in the…
-
Maintaining Momentum: CTN Renewal
Since 1990, the CTN has supported impactful research that has reduced new infections and improved the lives of…
-
Age, altruism, or a long-term view: Why do people living with HIV get the COVID-19 vaccine?
Understanding COVID-19 vaccine confidence in people living with HIV in Canada
-
New research comparing HIV medications set to change international recommendations
The WHO-funded study shows that dolutegravir is the optimal choice for first-line treatment of HIV
